NTLA vs. BMY

Last updated Jun 24, 2026

NTLA (Intellia Therapeutics, Inc.) and BMY (Bristol-Myers Squibb Company) are both stocks. Both are in the Healthcare sector — NTLA in Biotechnology, BMY in Drug Manufacturers - General. Over the past 10 years, NTLA returned -5.26%/yr vs 1.07%/yr for BMY. At a 0.22 correlation, their price movements are largely independent.

Performance

NTLA vs. BMY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Intellia Therapeutics, Inc. (NTLA) and Bristol-Myers Squibb Company (BMY). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, NTLA achieves a 69.63% return, which is significantly higher than BMY's 5.24% return. Over the past 10 years, NTLA has underperformed BMY with an annualized return of -5.26%, while BMY has yielded a comparatively higher 1.07% annualized return.

NTLA

• 1D: -3.17%
• 1M: 21.03%
• YTD: 69.63%
• 6M: 61.89%
• 1Y: 65.22%
• 3Y*: -28.07%
• 5Y*: -29.38%
• 10Y*: -5.26%

BMY

• 1D: 1.52%
• 1M: -6.61%
• YTD: 5.24%
• 6M: 4.58%
• 1Y: 24.26%
• 3Y*: -0.64%
• 5Y*: 0.61%
• 10Y*: 1.07%

*Multi-year figures are annualized to reflect compound growth (CAGR)

NTLA vs. BMY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
NTLA Intellia Therapeutics, Inc.	69.63%	-22.90%	-61.76%	-12.61%	-70.49%	117.35%	270.82%	7.47%	-28.98%	46.61%
BMY Bristol-Myers Squibb Company	5.24%	0.11%	15.81%	-26.14%	18.98%	2.88%	0.41%	27.74%	-12.90%	7.71%

Correlation

The correlation between NTLA and BMY is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.20
Correlation (3Y) Calculated over the trailing 3-year period	0.22
Correlation (5Y) Calculated over the trailing 5-year period	0.19
Correlation (10Y) Calculated over the trailing 10-year period	0.22
Correlation (All Time) Calculated using the full available price history since May 6, 2016	0.22

Fundamentals

Market Cap NTLA : $1.81B BMY : $113.48B
EPS NTLA : -$3.58 BMY : $3.57
PS Ratio NTLA : 25.43 BMY : 2.34
PB Ratio NTLA : 2.91 BMY : 5.65
Total Revenue (TTM) NTLA : $66.09M BMY : $48.48B
Gross Profit (TTM) NTLA : -$33.92M BMY : $33.33B
EBITDA (TTM) NTLA : -$299.32M BMY : $13.34B

Return for Risk

NTLA vs. BMY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

NTLA

NTLA Risk / Return Rank: 64
NTLA Sharpe Ratio Rank: 64
NTLA Sortino Ratio Rank: 67
NTLA Omega Ratio Rank: 69
NTLA Calmar Ratio Rank: 62
NTLA Martin Ratio Rank: 58

BMY

BMY Risk / Return Rank: 70
BMY Sharpe Ratio Rank: 70
BMY Sortino Ratio Rank: 66
BMY Omega Ratio Rank: 63
BMY Calmar Ratio Rank: 76
BMY Martin Ratio Rank: 74

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

NTLA vs. BMY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Intellia Therapeutics, Inc. (NTLA) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	NTLA	BMY	Difference
Sharpe ratio: Return per unit of total volatility	0.66	0.90	-0.24
Sortino ratio: Return per unit of downside risk	1.50	1.48	+0.02
Omega ratio: Gain probability vs. loss probability	1.21	1.17	+0.04
Calmar ratio: Return relative to maximum drawdown	0.92	1.95	-1.03
Martin ratio: Return relative to average drawdown	1.41	4.41	-3.00

NTLA vs. BMY - Sharpe Ratio Comparison

The current NTLA Sharpe Ratio is 0.66, which is comparable to the BMY Sharpe Ratio of 0.90. The chart below compares the historical Sharpe Ratios of NTLA and BMY, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

NTLA vs. BMY - Drawdown Comparison

The maximum NTLA drawdown since its inception was -96.45%, which is greater than BMY's maximum drawdown of -72.03%. Use the drawdown chart below to compare losses from any high point for NTLA and BMY.

Drawdown Indicators

	NTLA	BMY	Difference
Max Drawdown Largest peak-to-trough decline	-96.45%	-72.03%	-24.42%
Max Drawdown (1Y) Largest decline over 1 year	-71.27%	-12.53%	-58.74%
Max Drawdown (3Y) Largest decline over 3 years	-86.28%	-36.02%	-50.26%
Max Drawdown (5Y) Largest decline over 5 years	-96.45%	-47.67%	-48.78%
Max Drawdown (10Y) Largest decline over 10 years	-96.45%	-47.67%	-48.78%
Current Drawdown Current decline from peak	-91.37%	-20.09%	-71.28%
Average Drawdown Average peak-to-trough decline	-57.19%	-22.38%	-34.81%
Ulcer Index Depth and duration of drawdowns from previous peaks	46.34%	5.51%	+40.83%

Volatility

NTLA vs. BMY - Volatility Comparison

Intellia Therapeutics, Inc. (NTLA) has a higher volatility of 29.47% compared to Bristol-Myers Squibb Company (BMY) at 8.49%. This indicates that NTLA's price experiences larger fluctuations and is considered to be riskier than BMY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	NTLA	BMY	Difference
Volatility (1M) Calculated over the trailing 1-month period	29.47%	8.49%	+20.98%
Volatility (6M) Calculated over the trailing 6-month period	58.34%	18.04%	+40.30%
Volatility (1Y) Calculated over the trailing 1-year period	98.89%	26.96%	+71.93%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	81.41%	24.08%	+57.33%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	78.80%	25.30%	+53.50%

Dividends

NTLA vs. BMY - Dividend Comparison

NTLA has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 4.50%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
BMY Bristol-Myers Squibb Company	4.50%	4.60%	4.24%	4.44%	3.00%	2.36%	3.69%	2.55%	3.08%	2.55%	1.95%	2.17%
NTLA Intellia Therapeutics, Inc.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

Frequently Asked Questions

Can I hold both NTLA and BMY in my portfolio?

NTLA and BMY have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, NTLA or BMY?

NTLA has higher volatility (29.47%) compared to BMY (8.49%). In terms of maximum drawdown, NTLA dropped -96.45% vs BMY's -72.03%.

Which has better risk-adjusted returns?

BMY currently has the higher Sharpe Ratio (0.90 vs 0.66), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.